BeOne Medicines Ltd. — Director's Dealing 2019

Jun 7, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BeiGene, Ltd. (BGNE)
CIK: 0001651308
Period of Report: 2019-06-05

Reporting Person: Wang Xiaodong (Director, Chair, Scientific Advisory Brd)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-06-05	Share Option (Right to Buy)	$9.23	A	747708	Acquired	2029-06-04	Ordinary Shares (747708.0)	Direct

Footnotes

F1: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares.

F2: These securities vest over a four-year period as follows: 25% on June 5, 2020, and the remaining in 36 successive equal monthly installments, subject to continued service.